Figure 2.
Treatment patterns among MS (A), RRMS (B), and SPMS (C) patients’ cohorts at the inclusion (index-date).
Abbreviations: Mitox, mitoxantrone; IFN β-1A, interferon beta-1A; IFN β-1B, interferon beta-1B; Peg β-1A, peginterferon beta-1A; Glat, glatiramer acetate; Natal, natalizumab; Fing, fingolimod; Teriflu, teriflunomide; Alemt, alemtuzumab; DMF, dimethyl fumarate.